The results from the first large scale randomized control trial of Peptide Receptor Radionuclide Therapy (PRRT) were released last week at the European Cancer Congress 2015 meeting in Vienna, Austria. The data from the international NETTER-1 trial demonstrated increased progression free survival compared to high dose octreotide LAR for patients with advanced midgut neuroendocrine tumors. While available in many parts of the world, PRRT has not yet been approved for use in the US or other countries pending prospective randomized clinical trials (RCT). Having a positive RCT for PRRT should greatly expand access and availability to PRRT around the world. Click here to download the full release.
“With the results of the Netter-1 trial and the significant on-going work to demonstrate the effectiveness of other PRRT agents (including CFCF-sponsored research), hopefully the door will now open to making this therapy available and affordable throughout the US and beyond,” said Ron Hollander, Executive Director of NETRF. To view the medical abstract, click here. To watch a video of Dr. Philippe Ruszniewski discussing the results of the NETTER-1 study, click here.